Form 4: Inari Medical CEO Andrew Hykes Sells Shares Under 10b5-1 Trading Plan

Inari Medical's CEO, Andrew Hykes, sold 3,000 shares of common stock at $50 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Andrew Hykes, the President and CEO of Inari Medical, Inc., sold 3,000 shares of common stock on October 29, 2024.
• The sale was executed at a price of $50 per share.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on November 13, 2023.
• Following the transaction, Hykes directly owns 445,310 shares of Inari Medical common stock.
• Hykes also indirectly owns 1,550 shares through Child 1, 1,550 shares through Child 2, 1,550 shares through Child 3, and 1,000 shares through his spouse.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to an insider stock sale under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by insiders are a normal part of corporate governance, especially when executed under pre-arranged trading plans like Rule 10b5-1. These plans allow insiders to sell shares over a period of time without being accused of trading on non-public information.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially causing a slight decrease in stock price due to increased supply.
• The sale does not appear to have any immediate impact on employees, customers, suppliers, or creditors.

Key Dates